Table 1.
Technical Differences in the Generation of Precision-Cut Lung Slices
Step | Property | Variation | Notes/Examples |
---|---|---|---|
Lung filling | Agarose (%) | • 0.4–1.5 (36, 57, 72) | • Lower percentages are used in rodents, and larger ones are used in human tissue and bigger animals |
• 1.5–3 (15, 46) | |||
• The percentage of agarose may affect the mechanical properties of the filled tissue | |||
Media | • Salt solutions: PBS, EBSS, and HBSS (33, 73, 74) | • Some protocols add more supplements to the filling media, such as HEPES, penicillin/streptomycin, and Amphotericin B | |
• Cell culture medium: (D)MEM, DMEM/F-12, RPMI) (48, 72) | • The choice of filling media may influence the quality and survival of specific cell types within the PCLS | ||
Lung slicing | Media | • Salt-buffered solutions (16, 73, 75, 76) | • Most protocols use culture media for slicing with no alterations |
• Cell culture medium (15, 48, 57, 77) | • Some protocols supplement media with CaCl2, MgSO4, KCl, NaCl, NaH2PO4, glucose, NaHCO3, HEPES, penicillin/streptomycin, insulin, hydrocortisone, retinyl acetate, gentamicin, or Amphotericin B | ||
Devices | Tissue slicers (rotary chopping) (29) | • Krumdieck Slicer | |
• Compresstome VF-300 | |||
• Brendel Vitron Tissue Slicer | |||
Vibratome (74) | • Leica Vibratome VT1000 | ||
• Zeiss Hyrax Vibratory Microtome V55 | |||
• Campden 7000 SMZ-2 | |||
Thickness | • 150–225 μm (12, 74) | • Thinner PCLS are generally obtained from rodent tissue and allow for easier nutrient perfusion | |
• 250–500 μm (24, 48, 72, 73, 78) | |||
• Thicker PCLS are generally obtained from larger animal tissues or human tissue | |||
• No perfusion/diffusion problems have been reported for PCLS 500 μm thickness or less | |||
• Thicker PCLS allow for visualization of full alveolar spaces, improving the modeling aspects of specific diseases | |||
• The thickness of PCLS can vary for different CLDs | |||
• Slice thickness is usually optimized differently in each laboratory based on the research question | |||
Culture | Preparation | Agarose removal (79) | • Some protocols attempt to remove agarose from PCLS by repetitive washes within the first few hours after slicing |
• Agarose removal may allow for easier access to nutrients | |||
Pretreatment | • Most protocols replace media with varying initial incubation periods | ||
• Washing may be important for removal of secreted factors that may have been caused by the slicing (“cytokine storm”) | |||
Media | (D)MEM, Ham’s F-12, RPMI, Medium 199, EBSS, HBSS | • Several protocols use the same culture media during the procedure | |
• Additional supplements may include CaCl2, MgSO4, KCl, NaCl, NaH2PO4, glucose, NaHCO3, HEPES, penicillin/streptomycin, insulin, hydrocortisone, retinyl acetate, gentamicin, or Amphotericin B | |||
• The media needs to be optimized depending on the modeled disease | |||
Serum | • None | • Most protocols do not add serum to cultured PCLS because it might alter cell proliferation | |
• 0.1% (48) | |||
• 10% (72) | |||
Length | Minutes to a few hours | • Earlier studies used only short incubation times to study metabolites | |
1–7 d | • Most current PCLS models have shown viability across the different cell types for up to 7 d. Most of the discussed models use durations within this range | ||
>21 d (68, 80) | • Few studies have reported PCLS culture for up to 28 d. More recently, embedding in hydrogels was shown to extend culture times to >21 d |
Definition of abbreviations: CLDs = chronic lung diseases; DMEM = Dulbecco’s modified Eagle medium; EBSS = Earle’s balanced salt solution; HBSS = Hanks’ balanced salt solution; PCLS = precision-cut lung slices.